TY - JOUR
T1 - Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo
T2 - comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative design
AU - Luhata Lungayo, Christophe
AU - Burnett, Eleanor
AU - Mulumba, Audry
AU - Milabyo, Augustin
AU - Nasaka, Pablito
AU - Adhaku, Raymond
AU - Volatier, Etienne
AU - Tate, Jacqueline E.
AU - Parashar, Umesh
AU - Diallo, Alpha Oumar
AU - Burke, Rachel M.
AU - Otomba, John Samuel
AU - Dommergues, Marie Aliette
AU - Pukuta, Elisabeth
AU - Mwenda, Jason M.
AU - Ngoy, Francis
AU - Ngoy, Medard
AU - Mosala, Noela
AU - Muteba, Dominique
AU - Domingo, Dido Disengomoka
AU - Ditekemena, John
AU - Launay, Odile
AU - Jouffroy, Romain
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/12/5
Y1 - 2025/12/5
N2 - Background: Multinational rotavirus vaccines (Rotarix and RotaTeq) are 43 %–65 % effective in preventing hospitalizations due to rotavirus disease in African countries. The Rotasiil vaccine (Serum Institute of India) offers a potentially cost-effective option but lacks vaccine effectiveness (VE) estimates in African settings. We estimated Rotasiil VE against rotavirus hospitalizations in the Democratic Republic of Congo (DRC) using unconditional multivariate logistic regression and inverse probability of treatment weighting (IPTW) to adjust confounding. Methods: We examined sentinel surveillance data from two hospitals in Kinshasa (January 1, 2020 to December 31, 2023) for children aged ≤59 months who sought care for acute diarrhea. We used a test-negative case-control design and calculated VE as [1 – adjusted odds ratio (OR) × 100] using unconditional multivariate logistic regression. We compared two approaches to adjust the OR for confounding. First, the OR was adjusted by including the covariates in the model. Second, the OR was adjusted using stabilized IPTW. Results: In total, 310 children aged 6 to 30 months were included in the full rotavirus vaccine dose analysis, of which 118 (38 %) were rotavirus positive. The median age was 10 months (range: 8–14), and the proportion of fully vaccinated children was 87 %. The VE measured between fully vaccinated versus unvaccinated children was 60 % (95 % CI: 20–80) by multivariate logistic regression and 79 % (95 % CI: 71–85) by IPTW. Conclusion: Rotasiil vaccination under conditions of routine use effectively reduces rotavirus-associated diarrhea hospitalizations among children, supporting the ongoing use of rotavirus vaccine. The IPTW VE estimate was more precise than multivariate logistic regression but the confidence intervals overlapped, suggesting that the resulting VE estimates are not statistically different and the methods are complementary.
AB - Background: Multinational rotavirus vaccines (Rotarix and RotaTeq) are 43 %–65 % effective in preventing hospitalizations due to rotavirus disease in African countries. The Rotasiil vaccine (Serum Institute of India) offers a potentially cost-effective option but lacks vaccine effectiveness (VE) estimates in African settings. We estimated Rotasiil VE against rotavirus hospitalizations in the Democratic Republic of Congo (DRC) using unconditional multivariate logistic regression and inverse probability of treatment weighting (IPTW) to adjust confounding. Methods: We examined sentinel surveillance data from two hospitals in Kinshasa (January 1, 2020 to December 31, 2023) for children aged ≤59 months who sought care for acute diarrhea. We used a test-negative case-control design and calculated VE as [1 – adjusted odds ratio (OR) × 100] using unconditional multivariate logistic regression. We compared two approaches to adjust the OR for confounding. First, the OR was adjusted by including the covariates in the model. Second, the OR was adjusted using stabilized IPTW. Results: In total, 310 children aged 6 to 30 months were included in the full rotavirus vaccine dose analysis, of which 118 (38 %) were rotavirus positive. The median age was 10 months (range: 8–14), and the proportion of fully vaccinated children was 87 %. The VE measured between fully vaccinated versus unvaccinated children was 60 % (95 % CI: 20–80) by multivariate logistic regression and 79 % (95 % CI: 71–85) by IPTW. Conclusion: Rotasiil vaccination under conditions of routine use effectively reduces rotavirus-associated diarrhea hospitalizations among children, supporting the ongoing use of rotavirus vaccine. The IPTW VE estimate was more precise than multivariate logistic regression but the confidence intervals overlapped, suggesting that the resulting VE estimates are not statistically different and the methods are complementary.
KW - DRC
KW - IPTW
KW - Logistic regression
KW - Rotasiil
KW - Rotavirus gastroenteritis
KW - Vaccine effectiveness
UR - https://www.scopus.com/pages/publications/105021227359
U2 - 10.1016/j.vaccine.2025.127944
DO - 10.1016/j.vaccine.2025.127944
M3 - Article
C2 - 41218304
AN - SCOPUS:105021227359
SN - 0264-410X
VL - 68
JO - Vaccine
JF - Vaccine
M1 - 127944
ER -